

- **Name:** **Changhoon Yoo**
  - **Current Position & Affiliation:** **Assistant Professor, Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine**
  - **Country:** **Korea**
- 

- **Educational Background:** MD University of Ulsan College of Medicine  
PhD University of Ulsan College of Medicine

- **Professional Experience:**

2007-2011: Resident, Department of Internal Medicine, Asan Medical Center  
2014-2016: Clinical Fellow, Department of Oncology, Asan Medical Center  
2016-Present: Assistant Professor, Department of Oncology, Asan Medical Center

- **Professional Organizations:** KSMO, KCA, ASCO, ESMO

- **Main Scientific Publications:**

1. **Yoo C**, Oh DY, Choi HJ, Kudo M, Ueno M, Kondo S, Chen LT, Osada M, Helwig C, Dussault I, Ikeda M. Phase I study of bintrafusp alfa, a bifunctional fusion protein targeting TGF- $\beta$  and PD-L1, in patients with pretreated biliary tract cancer. *J Immunother Cancer*. 2020 May;8(1):e000564. doi: 10.1136/jitc-2020-000564.
2. **Yoo C**, Byeon S, Bang Y, Cheon J, Kim JW, Kim JH, Chon HJ, Kang B, Kang MJ, Kim I, Hwang JE, Kang JH, Lee MA, Hong JY, Lim HY, Ryoo BY. Regorafenib in previously treated advanced hepatocellular carcinoma: Impact of prior immunotherapy and adverse events. *Liver Int*. 2020 May 25. doi: 10.1111/liv.14496. Online ahead of print.
3. **Yoo C**, Lee SS, Song KB, Jeong JH, Hyung J, Park DH, Song TJ, Seo DW, Lee SK, Kim MH, Lee SS, Kim JH, Jin HS, Park JH, Hwang DW, Lee JH, Lee W, Chang HM, Kim KP, Ryoo BY, Kim SC. Neoadjuvant modified FOLFIRINOX followed by postoperative gemcitabine in borderline resectable pancreatic adenocarcinoma: a Phase 2 study for clinical and biomarker analysis. *Br J Cancer*. 2020 May 20. doi: 10.1038/s41416-020-0867-x. Online ahead of print.
4. Chae H, Kim D, **Yoo C\***, Kim KP, Jeong JH, Chang HM, Lee SS, Park DH, Song TJ, Hwang S, Kim KH, Song GW, Ahn CS, Lee JH, Hwang DW, Kim SC, Jang SJ, Hong SM, Kim TW, Ryoo BY. Therapeutic relevance of targeted sequencing in management of patients with advanced biliary tract cancer: DNA damage repair gene

- mutations as a predictive biomarker. *Eur J Cancer*. 2019 Aug 30;120:31-39. doi: 10.1016/j.ejca.2019.07.022. [Epub ahead of print] **\*Co-corresponding author**
5. **Yoo C**, Ryu MH, Na YS, Ryoo BY, Park SR, Kang YK. Analysis of serum protein biomarkers, circulating tumor DNA, and dovitinib activity in patients with tyrosine kinase inhibitor-refractory gastrointestinal stromal tumors. *Annals of Oncology*. 2014 Nov;25(11):2272-7.
  6. **Yoo C**, Ryu MH, Kang BW, Yoon SK, Ryoo BY, Chang HM, et al. Cross-Sectional Study of Imatinib Plasma Trough Levels in Patients With Advanced Gastrointestinal Stromal Tumors: Impact of Gastrointestinal Resection on Exposure to Imatinib. *Journal of Clinical Oncology*. 2010 Mar 18;28(9):1554-9.